Atrial Fibrillation, Stroke, Ischemic
Conditions
Brief summary
This study explores the association of symptomatic episodes of atrial fibrillation (AF) occurrence and long-term risk of thromboembolic complications in a retrospective setting.
Detailed description
The study population consists of the FinCV-dataset, which includes 7660 acute cardioversions for atrial fibrillation. The electronic patient records of FinCV-study patients are reviewed to collect data on anticoagulation, number of cardioversions as well as mortality and stroke data. We seek to explore the possible association between the frequency of AF paroxysms in low stroke risk patients and the occurrence of death, stroke and major bleed as well as the net clinical benefit of anticoagulation. Data collection is performed by reviewing electronic patient records.
Interventions
Long term oral anticoagulation with VKA (vitamin K antagonist) or NOAC (non-vitamin K oral anticoagulant)
Sponsors
University of Turku
Study design
Observational model
CASE_CONTROL
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* primary diagnosis of atrial fibrillation (ICD-10 code I48) * Cardioversion for acute (\<48 h) atrial fibrillation * \>18 years of age * living within the catchment area of the hospital
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Death | From the first cardioversion through study completion, an average of 6 years | Death from any cause |
| Ischemic stroke or TIA (transient ischemic attack) | From the first cardioversion through study completion, an average of 6 years | Ischemic stroke or TIA diagnosed by neurologist |
| Major Bleed | From the first cardioversion through study completion, an average of 6 years | Major Bleeding complication according to ISTH (International Society on Thrombosis and Haemostasis) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Permanent oral anticoagulation | From the first cardioversion through study completion, an average of 6 years. | Initiation of permanent oral anticoagulation therapy, information on oral anticoaglation initiation done by reviewing electronic patient records |
Countries
Finland
Outcome results
None listed